Compare
Schrodinger, Inc. vs Arvinas, Inc. vs Ligand Pharmaceuticals Inc vs Keros Therapeutics, Inc.
| Latest fiscal year | Schrodinger, Inc. SDGR | Arvinas, Inc. ARVN | Ligand Pharmaceuticals Inc LGND | Keros Therapeutics, Inc. KROS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $255.87M | $262.60M | $268.09M | $244.06M |
| Revenue growth (YoY) | +23.3% | -0.3% | +60.4% | n/m |
| Gross margin | 55.7% | n/a | n/a | n/a |
| Operating margin | -65.2% | -45.1% | 15.3% | 27.7% |
| Net margin | -40.4% | -30.8% | 46.4% | 35.7% |
| Net income | -$103.27M | -$80.80M | $124.45M | $87.01M |
| EPS (Diluted) | -$1.41 | -$1.14 | $6.13 | $2.30 |
| Operating cash flow | $13.90M | -$273.80M | $49.36M | $107.50M |
| Free cash flow | $12.46M | -$275.70M | $48.91M | $105.95M |
| Cash & equivalents | $230.52M | $142.90M | $174.93M | $287.42M |
| Total assets | $726.16M | $717.90M | $1.56B | $338.02M |
| Total liabilities | $362.11M | $284.00M | $543.42M | $34.89M |
| Shareholders' equity | $364.05M | $433.90M | $1.02B | $303.13M |
| Return on year-end equity | -28.4% | -18.6% | 12.2% | 28.7% |
| Shares outstanding | n/a | 63.50M | 19.77M | 19.54M |
Revenue, most recent five fiscal years
| Fiscal year | Schrodinger, Inc. | Arvinas, Inc. | Ligand Pharmaceuticals Inc | Keros Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $255.87M Ended 2025-12-31 | $262.60M Ended 2025-12-31 | $268.09M Ended 2025-12-31 | $244.06M Ended 2025-12-31 |
| 1 year earlier | $207.54M Ended 2024-12-31 | $263.40M Ended 2024-12-31 | $167.13M Ended 2024-12-31 | $3.55M Ended 2024-12-31 |
| 2 years earlier | $216.67M Ended 2023-12-31 | $78.50M Ended 2023-12-31 | $131.31M Ended 2023-12-31 | $151.0K Ended 2023-12-31 |
| 3 years earlier | $180.96M Ended 2022-12-31 | $131.40M Ended 2022-12-31 | $196.25M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $137.93M Ended 2021-12-31 | $53.60M Ended 2021-12-31 | $241.54M Ended 2021-12-31 | $20.10M Ended 2021-12-31 |